Department of Neurology, Oregon Health and Science University, Portland, Oregon, USA.
Advanced Imaging Research Center, Oregon Health and Science University, Portland, Oregon, USA.
Magn Reson Med. 2018 Jul;80(1):224-230. doi: 10.1002/mrm.27028. Epub 2017 Dec 4.
Delayed ferumoxytol enhancement on T -weighted images appears visually similar to gadoteridol enhancement. The purpose of this study was to quantitatively compare ferumoxytol T enhancement to gadoteridol enhancement with an objective, semi-automated method.
206 sets of post-gadoteridol and 24 h post-ferumoxytol T -weighted scans from 58 high grade glioma patients were analyzed (9 pre-chemoradiation, 111 < 90 days post-chemoradiation, 21 > 90 days post-chemoradiation, 65 post-bevacizumab scans). Enhancement volumes and signal intensities normalized to normal appearing tissue proximal to enhancement were calculated with a semi-automated method. Enhancement cube root volumes (D) and signal intensities (SI) were compared between the 2 contrast agents, and relative difference of D and SI were compared in different treatment groups with multivariate analysis. Within patient differences in D and SI before and after treatment with bevacizumab or steroid were assessed in 26 patients in each treatment group.
When compared to gadoteridol, ferumoxytol D was 13.83% smaller and SI was 7.24% lower (P < 0.0001). The relative differences in D and SI between the 2 contrast agents were not significantly different between treatment groups (P > 0.05). Relative difference in D and SI did not change significantly in response to bevacizumab (P = 0.5234 and P = 0.2442, respectively) or to steroid (P = 0.3774, P = 0.0741) in the within patient comparison.
The correlation between the 2 contrast agents' enhancement size and signal intensity and their similar behavior in response to therapy suggest that ferumoxytol can be used for revealing enhancement in high grade glioma patients. Magn Reson Med 80:224-230, 2018. © 2017 International Society for Magnetic Resonance in Medicine.
T 加权图像上延迟的 Ferumoxytol 增强在视觉上类似于钆特醇增强。本研究的目的是用一种客观的、半自动的方法定量比较 Ferumoxytol T 增强与钆特醇增强。
分析了 58 例高级别胶质瘤患者的 206 套钆特醇后和 24 小时 Ferumoxytol T 加权扫描（9 例化疗前，111 例<90 天化疗后，21 例>90 天化疗后，65 例贝伐单抗后扫描）。使用半自动方法计算增强体积和信号强度，归一化为增强近端正常组织。用半自动化方法计算 Ferumoxytol 和钆特醇的增强体积和信号强度。采用多元分析比较两种对比剂的增强体根体积（D）和信号强度（SI），并比较不同治疗组的 D 和 SI 的相对差异。在贝伐单抗或激素治疗的 26 例患者中，评估治疗前后 D 和 SI 的个体内差异。
与钆特醇相比，Ferumoxytol D 小 13.83%，SI 低 7.24%（P<0.0001）。两种对比剂的 D 和 SI 之间的相对差异在不同治疗组之间无显著差异（P>0.05）。在个体内比较中，贝伐单抗（P=0.5234 和 P=0.2442）或激素（P=0.3774，P=0.0741）对 D 和 SI 的相对差异无明显变化。
Ferumoxytol 与钆特醇的增强大小和信号强度之间的相关性及其对治疗的相似反应表明，Ferumoxytol 可用于显示高级别胶质瘤患者的增强。磁共振医学 80:224-230,2018。2017 年国际磁共振医学学会。
